Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ZANUBRUTINIB for Marginal zone lymphoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 97 adverse event reports in the FDA FAERS database where ZANUBRUTINIB was used for Marginal zone lymphoma.

Most Reported Side Effects for ZANUBRUTINIB

Side Effect Reports % Deaths Hosp.
Off label use 376 13.4% 43 116
Disease progression 224 8.0% 41 26
Contusion 165 5.9% 3 23
Myelosuppression 147 5.3% 4 68
Fatigue 146 5.2% 13 34
Rash 134 4.8% 5 20
Death 120 4.3% 120 15
White blood cell count decreased 119 4.3% 9 37
Platelet count decreased 112 4.0% 9 37
Anaemia 102 3.7% 11 20
Diarrhoea 101 3.6% 12 22
Pneumonia 100 3.6% 21 55
Covid-19 89 3.2% 17 40
Drug ineffective 87 3.1% 24 27
Asthenia 81 2.9% 10 30

Other Indications for ZANUBRUTINIB

Chronic lymphocytic leukaemia (726) Waldenstrom's macroglobulinaemia (429) Product used for unknown indication (418) Mantle cell lymphoma (329) Diffuse large b-cell lymphoma (251) B-cell small lymphocytic lymphoma (74) B-cell lymphoma (73) Follicular lymphoma (68) Lymphoma (64) Non-hodgkin's lymphoma (62)

Other Drugs Used for Marginal zone lymphoma

RITUXIMAB (706) IBRUTINIB (519) LENALIDOMIDE (321) OBINUTUZUMAB (188) ETOPOSIDE (176) BENDAMUSTINE (174) CYCLOPHOSPHAMIDE (173) IFOSFAMIDE (151) METHOTREXATE (138) DOXYCYCLINE (135)

Related Pages

ZANUBRUTINIB Full Profile All Marginal zone lymphoma Drugs ZANUBRUTINIB Demographics ZANUBRUTINIB Timeline